Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodiesReport as inadecuate




Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies - Download this document for free, or read online. Document in PDF available to download.

Clinical and Experimental Medicine

, 6:1

Received: 17 December 2005Accepted: 17 December 2005

Abstract

CD20 has proven to be an excellent target for the treatment of B-cell lymphoma, first for the chimeric monoclonal antibody rituximab Rituxan™, and more recently for the radiolabelled antibodies Y-90 ibritumomab tiuxetan Zevalin™ and I-131 tositumomab Bexxar™. Radiation therapy effects are due to beta emissions with path lengths of 1–5 mm; gamma radiation emitted by I-131 is the only radiation safety issue for either product. Dose-limiting toxicity for both radiolabelled antibodies is reversible bone marrow suppression. They produce response rates of 70%–90% in low-grade and follicular lymphoma and 40%–50% in transformed low-grade or intermediate-grade lymphomas. Both products produce higher response rates than related unlabelled antibodies, and both are highly active in patients who are relatively resistant to rituximab-based therapy. Median duration of response to a single course of treatment is about 1 year with complete remission rates that last 2 years or longer in about 25% of patients. Clinical trials suggest that anti- CD20 radioimmunotherapy is superior to total body irradiation in patients undergoing stem cell supported therapy for B-cell lymphoma, and that it is a safe and efficacious modality when used as consolidation therapy following chemotherapy. Among cytotoxic treatment options, current evidence suggests that one course of anti-CD20 radioimmunotherapy is as efficacious as six to eight cycles of combination chemotherapy. A major question that persists is how effective these agents are in the setting of rituximab- refractory lymphoma. These products have been underutilised because of the complexity of treatment coordination and concerns regarding reimbursement.

Key words CD20 B-cell lymphoma Y-90 ibritumomab tiuxetan I-131 tositumomab  Download fulltext PDF



Author: R. O. Dillman

Source: https://link.springer.com/







Related documents